Recursion Pharmaceuticals, Inc. (RXRX) Misses Q3 EPS by 4c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $10.53 million versus the consensus estimate of $11.24 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
• Pinnacle Bank (PBNK) Tops Q2 EPS by 25c
• Bogota Financial Corp. (BSBK) Reports Q2 EPS of $0.06